Table 2.
Clinical and laboratory features of AMAN and AMSAN groups
| All Cases | Axonal subtypes | p (AMAN/AMSAN) | |||||
|---|---|---|---|---|---|---|---|
| AMAN n=61 | AMSAN n=21 | ||||||
| M/F | 1.79 | 1.77 | 1.85 | NS | |||
| Most common antecedent infection (%) | URTI (62.9) | URTI (63.9) | URTI (60) | NS | |||
| Cranial nerve involvement% | 20 | 21 | 18.7 | NS | |||
| Ventilation requirement% | 12.8 | 8.6 | 25 | NS | |||
| Min-Max | Median (iq range*) | Min-Max | Median (iq range) | Min-Max | Median (iq range) | ||
| Duration of weakness (days) | 1–60 | 6 (3–10) | 1–60 | 6 (3.25–9) | 2–30 | 7 (3.5–10) | NS |
| CSF protein mg/dl | 13–323 | 83 (48.5–23.5) | 13–323 | 78 (50–122) | 15–202 | 98 (34.5–117) | NS |
| Duration of hospitalization (days) | 2–140 | 10 (8–16.5) | 2–100 | 11 (8–18) | 3–140 | 9.5 (6.75–17) | NS |
| Clinical score | |||||||
| admission | 2–5 | 4 (3–4) | 2–5 | (4–4) | 3–5 | 4 (3–5) | NS |
| discharge | 0–5 | 3 (2–4) | 0–4 | 3 (2–4) | 1–5 | 3 (2–4) | NS |
| 1 month | 0–5 | 1 (0–3) | 0–4 | 2 (0–3) | 0–5 | 1 (0–2.5) | NS |
| 3 months | 0–5 | 1 (0–2) | 0–4 | 1 (0–2.5) | 0–5 | 1 (0–2.5) | NS |
| 6 months | 0–5 | 0 (0–1) | 0–3 | 0 (0–1) | 0–5 | 0 (0–4) | NS |
| 12 months | 0–5 | 0 (0–1) | 0–3 | 0 (0–1) | 0–5 | 0 (0–3) | NS |
*
interquartile range; URTI, Upper respiratory tract infection.